학술논문
Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
CASE SERIES
CASE SERIES
Document Type
Report
Source
International Medical Case Reports Journal. April 2019, p93, 10 p.
Subject
Language
English
ISSN
1179-142X
Abstract
Introduction Diabetic retinopathy is a microvascular complication of type 1 and 2 diabetes mellitus that is caused by damage to the blood vessels of the retina. It affects one in [...]
Objective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 [mu]g/day fluocinolone acetonide [FAc] intravitreal implant (ILUVIEN[R]) in patients with persistent or recurrent diabetic macular edema (DME) and 6-18 months of follow-up. Methods: Retrospective case series in 18 eyes (13 patients) treated with the FAc implant. Prior to the implant, eyes were treated with an anti-VEGF therapy, dexamethasone implant, or focal or panretinal photocoagulation. Effectiveness outcomes included changes in visual acuity and macular edema. Safety outcomes included intraocular pressure (IOP) changes, IOP drugs, and IOP-related surgeries/interventions. Treatment burden was assessed by comparing the number of DME treatments before and after FAc implantation. Results: The FAc implant reduced macular volume in 16/18 (89%) eyes, with a statistically significant mean change of -1.33 mm (3) (p=0.001). The average central retinal thickness reduction for all 18 eyes was statistically significant, decreasing from 444 [mu]m at baseline to 359 [mu]m after the FAc implant (p Conclusion: The FAc implant is an appropriate option to incorporate earlier in the DME treatment process, leading to positive long-term outcomes with an acceptable safety profile, and a reduced treatment burden for patients, and reduced clinical staff time. Keywords: persistent diabetic macular edema, recurrent diabetic macular edema, DME, visual acuity, macular volume, fluocinolone acetonide implant
Objective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 [mu]g/day fluocinolone acetonide [FAc] intravitreal implant (ILUVIEN[R]) in patients with persistent or recurrent diabetic macular edema (DME) and 6-18 months of follow-up. Methods: Retrospective case series in 18 eyes (13 patients) treated with the FAc implant. Prior to the implant, eyes were treated with an anti-VEGF therapy, dexamethasone implant, or focal or panretinal photocoagulation. Effectiveness outcomes included changes in visual acuity and macular edema. Safety outcomes included intraocular pressure (IOP) changes, IOP drugs, and IOP-related surgeries/interventions. Treatment burden was assessed by comparing the number of DME treatments before and after FAc implantation. Results: The FAc implant reduced macular volume in 16/18 (89%) eyes, with a statistically significant mean change of -1.33 mm (3) (p=0.001). The average central retinal thickness reduction for all 18 eyes was statistically significant, decreasing from 444 [mu]m at baseline to 359 [mu]m after the FAc implant (p Conclusion: The FAc implant is an appropriate option to incorporate earlier in the DME treatment process, leading to positive long-term outcomes with an acceptable safety profile, and a reduced treatment burden for patients, and reduced clinical staff time. Keywords: persistent diabetic macular edema, recurrent diabetic macular edema, DME, visual acuity, macular volume, fluocinolone acetonide implant